Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

Observational, Longitudinal, Prospective, French, Multicentre Study Conducted on Adult and Paediatric Patients Treated With Micafungin in Prophylaxis and Followed Over a 3 Months' Period in Routine Medical Practice

The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.

Inclusion Criteria:

• Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.
• Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.
• Patient initiating antifungal prophylaxis with micafungin.

Exclusion Criteria:

• Patient presenting documented fungal infection.
• Patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.